OptimizeRx Corp
corporate_fare Company Profile
OptimizeRx Corp (NASDAQ:OPRX) is a publicly traded company in the Trade & Services sector. Wiseek has independently scored 14 items for OPRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-12, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for OPRX spans 8-K, DEFA14A, 10-Q, DEF 14A.
Recent high-impact activity:
- OptimizeRx CFO Stelmakh to Exit; D'Silva and Favazza Promoted; Q2 Revenue Falls 30%
- OptimizeRx Q2 Revenue Falls 30% to $20.5M, Reaffirms FY26 Guidance
- Shareholders Approve 1M Equity Plan Shares, Reject Evergreen Dilution Provision
- OptimizeRx Details CCO Separation Agreement, $589K Payout
- OptimizeRx Urges Shareholder Approval for Evergreen Equity Plan, Allowing Over 30% Potential Dilution
Financial Snapshot
Short Interest & Short Volume
9.31 days to coverFINRA reported short interest of 1,008,836 shares in OPRX as of the September 15, 2026 settlement, a 13.1% decrease from the prior period — about 9.3 days to cover at its recent average daily volume. On October 2, 2026, 60.5% of OPRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.